Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

Published:2016-09-07 Issue:355 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Turtle Cameron J.¹²,Hanafi Laïla-Aïcha¹,Berger Carolina¹²,Hudecek Michael¹,Pender Barbara¹,Robinson Emily¹,Hawkins Reed¹,Chaney Colette¹,Cherian Sindhu³,Chen Xueyan³,Soma Lorinda³,Wood Brent³,Li Daniel⁴,Heimfeld Shelly¹,Riddell Stanley R.¹²,Maloney David G.¹²

Affiliation:

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

2. Department of Medicine, University of Washington, Seattle, WA 98109, USA.

3. Department of Laboratory Medicine, University of Washington, Seattle, WA 98109, USA.

4. Juno Therapeutics, Seattle, WA 98109, USA.

Abstract

A CD19 chimeric antigen receptor–modified T cell product with defined composition has potent antitumor activity.

Funder

National Cancer Institute

National Institute of Diabetes and Digestive and Kidney Diseases

NCI

Life Science Discovery Fund

Bezos Family Foundation

Juno Therapeutics

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference39 articles.

1. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

2. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

3. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

4. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

5. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Cited by 860 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

3. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy;Frontiers in Immunology;2024-09-12

4. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

5. TCR/CD3-based synthetic antigen receptors (TCC) convey superior antigen sensitivity combined with high fidelity of activation;Science Advances;2024-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3